XML 90 R79.htm IDEA: XBRL DOCUMENT v3.23.3
Income Tax Expense - Disclosure of Reconciliation of Income Tax Expense to Prima Facie Tax Payable (Detail) - AUD ($)
 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Loss before income tax expense $ (39,896,348) $ (32,210,792) $ (29,902,591)
Tax at the Australian tax rate of 25% (2022:25%, 2021:26%) (9,974,087) (8,052,698) (7,774,674)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:      
Non-deductible share based payments 500,393 371,710 464,324
Other non-deductible expenses 332,523 1,485,059 1,239,756
Non-assessable income (828,500) (783,318) (541,122)
Deductible capital listing fee (507,561) (368,398) (259,458)
Adjustment of current tax for prior period   148,303 0
Difference in overseas tax rates [1] 5,442,226 4,118,372 2,132,187
Income tax expense before adjustment (5,035,006) (3,080,970) (4,738,987)
Net adjustment to deferred tax assets and liabilities for tax losses and temporary differences not recognized 5,035,006 3,080,936 4,738,954
Income tax expense $ 0 $ 34 [2] $ 33 [2]
[1] Difference in overseas tax rate is largely as a result of the corporate income tax rate of 10% applicable to the Immutep subsidiary in France for fiscal year 2023, 2022 and 2021.
[2] Income tax expense relates to tax payable for the Immutep subsidiary in the United States.